OOIR: Observatory of International Research

Papers

(The H4-Index of Archiv der Pharmazie is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Discovery of sulfadrug–pyrrole conjugates as carbonic anhydrase and acetylcholinesterase inhibitors	184
1,2,3‐Triazole hybrids as anticancer agents: A review	150
Novel benzoic acid derivatives: Synthesis and biological evaluation as multitarget acetylcholinesterase and carbonic anhydrase inhibitors	70
Novel metabolic enzyme inhibitors designed through the molecular hybridization of thiazole and pyrazoline scaffolds	69
1,3,5‐Triazine: A versatile pharmacophore with diverse biological activities	62
Design, synthesis, and biological activity of novel dithiocarbamate‐methylsulfonyl hybrids as carbonic anhydrase inhibitors	56
Recent update on antibacterial and antifungal activity of quinoline scaffolds	52
Design and discovery of new 1,2,4‐triazolo[4,3‐c]quinazolines as potential DNA intercalators and topoisomerase II inhibitors	50
Pharmacophore‐linked pyrazolo[3,4‐d]pyrimidines as EGFR‐TK inhibitors: Synthesis, anticancer evaluation, pharmacokinetics, and in silico mechanistic studies	49
Synthesis and in vitro carbonic anhydrases and acetylcholinesterase inhibitory activities of novel imidazolinone‐based benzenesulfonamides	45
Toad venom: A comprehensive review of chemical constituents, anticancer activities, and mechanisms	43
Phthalazine‐based VEGFR‐2 inhibitors: Rationale, design, synthesis, in silico, ADMET profile, docking, and anticancer evaluations	39
Synthesis of N‐alkylated pyrazolo[3,4‐d]pyrimidine analogs and evaluation of acetylcholinesterase and carbonic anhydrase inhibition properties	36
Design, synthesis, molecular modeling, and antimicrobial potential of novel 3‐[(1H‐pyrazol‐3‐yl)imino]indolin‐2‐one derivatives as DNA gyrase inhibitors	35
Discovery of novel pyrazole and pyrazolo[1,5‐a]pyrimidine derivatives as cyclooxygenase inhibitors (COX‐1 and COX‐2) using molecular modeling simulation	34
In vivo‐ and in silico‐driven identification of novel synthetic quinoxalines as anticonvulsants and AMPA inhibitors	33
Anticancer activity of novel 3‐(furan‐2‐yl)pyrazolyl and 3‐(thiophen‐2‐yl)pyrazolyl hybrid chalcones: Synthesis and in vitro studies	33
Synthesis and biological evaluation of some 1‐naphthol derivatives as antioxidants, acetylcholinesterase, and carbonic anhydrase inhibitors	32
Pyridine‐derived VEGFR‐2 inhibitors: Rational design, synthesis, anticancer evaluations, in silico ADMET profile, and molecular docking	31
New 1,3,4‐oxadiazoles linked with the 1,2,3‐triazole moiety as antiproliferative agents targeting the EGFR tyrosine kinase	31
Oxadiazole: A highly versatile scaffold in drug discovery	31
Cinnamic acid hybrids as anticancer agents: A mini‐review	30
Design, synthesis, docking, ADMET profile, and anticancer evaluations of novel thiazolidine‐2,4‐dione derivatives as VEGFR‐2 inhibitors	30
Azetidines of pharmacological interest	28
Design, synthesis, molecular docking, and some metabolic enzyme inhibition properties of novel quinazolinone derivatives	27

N‐Substituted‐4‐phenylphthalazin‐1‐amine‐derived VEGFR‐2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluation studies	27
Synthesis, characterization, and biological evaluation of some novel Schiff bases as potential metabolic enzyme inhibitors	26